Clinical Trial Update: A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen [Phase 1]

View source ↗

Summary

Phase 1 study evaluating intravenous trastuzumab-MCC-DM1 in HER2-positive metastatic breast cancer patients who previously received a trastuzumab-containing reg…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab-MCC-DM1 (ado-trastuzumab emtansine)

Snippet

Sponsor: Genentech, Inc. | Conditions: Metastatic Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2015-07-30